Physician profile
Marc Laufe
NPI 1891780490
$14,985.09
in general payments reported to CMS, 2019-2025
26 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,207 · 2020: $569 · 2021: $863 · 2022: $2,154 · 2023: $3,247 · 2024: $1,180 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Consulting Fee: $1,620 · Travel and Lodging: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.17 |
| Consulting Fee | $1,620.00 |
| Travel and Lodging | $824.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,750.83 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $4,306.07 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $1,345.65 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $634.56 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $390.70 | 2019-2025 | Winrevair, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.52 | 2019-2025 | Stiolto Respimat, Ofev, Jascayd |
| Verona Pharma, INC. | $358.21 | 2025 | Ohtuvayre |
| Insmed, INC. | $302.27 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $293.80 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $274.07 | 2021-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $141.73 | 2025 | Glassia, Cuvitru |
| United Therapeutics Corporation | $124.86 | 2024-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $117.04 | 2022-2025 | Nuzyra |
| Ambu INC. | $115.50 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $109.93 | 2019-2025 | Opsumit, Uptravi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $56.77 | 2024-2025 | Smartvest |
| Baxter Healthcare | $52.32 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $50.07 | 2019-2022 | |
| Philips North America LLC | $42.35 | 2019-2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $38.06 | 2019 | |
| Cvrx, INC. | $24.07 | 2025 | Barostim Neo System |
| Viatris Specialty LLC | $22.50 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $15.45 | 2025 | |
| Pfizer INC. | $14.97 | 2025 | |
| Lilly USA, LLC | $14.42 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Laufe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.